Nearly eight months after debuting on the Nasdaq for $17 a share, late-stage biopharmaceutical company Arcutis Biotherapeutics has seen explosive growth in many aspects, including its stock price, which has gone up by $7.66, and its staff count, which has doubled to more than 50 since the start of the year.

The Westlake Village company even will have to move its headquarters down the street on Townsgate Road to accommodate a need for more space.


Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 26 biweekly issues
  • Subscriber-only digital content for prime stories
  • Book of Lists — the most comprehensive business resource in the Valley region
Yours for only $49